BACKGROUND: Upadacitinib has proven to be well tolerated and provided superior efficacy compared to dupilumab after 16 weeks of treatment in adult patients with moderate-to-severe atopic dermatitis (AD) in randomized clinical trials. METHODS: This multicentric, prospective, observational, real-life study included 120 adult patients with moderate-to-severe AD treated with Upadacitinib at 10 Italian hospitals. We examined both physician-reported outcome measures (EASI), patient-reported outcome measures (itch, sleep and pain score [NRS], Dermatology Life Quality Index [DLQI], alexithymia [TAS-20 score]), and serological markers after 16 weeks. RESULTS: A statistically significant reduction was recorded in all the scores analyzed, including the TAS-20 score (P<0.0001). The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was 90.1 (11.3) (P<0.0001). The EASI50, EASI75 and EASI90 response rates were 95.8%, 82.5%, 50.8% (P<0.0001). CONCLUSIONS: This is the broadest multicenter real-life study in AD patients treated with upadacitinib, analyzing the reduction of the TAS-20 score. Noteworthy is the rapidity of drug effectiveness in reducing the extension of lesions and itching after just four weeks.
Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study
Patella, Vincenzo;Triggiani, Massimo;Carrieri, Isabella;Pugliese, Francesco;
2025
Abstract
BACKGROUND: Upadacitinib has proven to be well tolerated and provided superior efficacy compared to dupilumab after 16 weeks of treatment in adult patients with moderate-to-severe atopic dermatitis (AD) in randomized clinical trials. METHODS: This multicentric, prospective, observational, real-life study included 120 adult patients with moderate-to-severe AD treated with Upadacitinib at 10 Italian hospitals. We examined both physician-reported outcome measures (EASI), patient-reported outcome measures (itch, sleep and pain score [NRS], Dermatology Life Quality Index [DLQI], alexithymia [TAS-20 score]), and serological markers after 16 weeks. RESULTS: A statistically significant reduction was recorded in all the scores analyzed, including the TAS-20 score (P<0.0001). The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was 90.1 (11.3) (P<0.0001). The EASI50, EASI75 and EASI90 response rates were 95.8%, 82.5%, 50.8% (P<0.0001). CONCLUSIONS: This is the broadest multicenter real-life study in AD patients treated with upadacitinib, analyzing the reduction of the TAS-20 score. Noteworthy is the rapidity of drug effectiveness in reducing the extension of lesions and itching after just four weeks.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
